Collegium Pharmaceutical, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Collegium Pharmaceutical, Inc. (COLL) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$555.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$15.05M, a 225.60% decline year-over-year.
- Collegium Pharmaceutical, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was $14.50M, a 499.75% increase year-over-year.
- Collegium Pharmaceutical, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was $16.96M, a 35.31% increase year-over-year.
- Collegium Pharmaceutical, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was $31.51M, a 237.51% increase year-over-year.
- Collegium Pharmaceutical, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was $62.87M, a 9.13% decline from fiscal 2024.
- Collegium Pharmaceutical, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was $69.19M, a 43.68% increase from fiscal 2023.
- Collegium Pharmaceutical, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was $48.16M.
- Collegium Pharmaceutical, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$25.00M, a 134.96% decline from fiscal 2021.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$15.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$555.00K 10-Q · filed 2026-08-06 | $16.41M derived: sum of 3 quarters · filed 2026-08-06 | $47.91M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $14.50M 10-Q · filed 2026-05-07 | $31.46M derived: sum of 2 quarters · filed 2026-05-07 | $62.97M derived: sum of 3 quarters · filed 2026-05-07 | $74.95M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $16.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $48.47M derived: sum of 2 quarters · filed 2026-02-26 | $60.45M derived: sum of 3 quarters · filed 2026-08-06 | $62.87M 10-K · filed 2026-02-26 |
| 2025-09-30 | $31.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $43.49M derived: sum of 2 quarters · filed 2026-08-06 | $45.91M 10-Q · filed 2025-11-06 | $58.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $11.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $14.40M 10-Q · filed 2026-08-06 | $26.94M derived: sum of 3 quarters · filed 2026-08-06 | $36.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.42M 10-Q · filed 2026-05-07 | $14.95M derived: sum of 2 quarters · filed 2026-05-07 | $24.29M derived: sum of 3 quarters · filed 2026-05-07 | $43.89M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $12.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $21.87M derived: sum of 2 quarters · filed 2026-02-26 | $41.48M derived: sum of 3 quarters · filed 2026-02-26 | $69.19M 10-K · filed 2026-02-26 |
| 2024-09-30 | $9.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $28.94M derived: sum of 2 quarters · filed 2025-11-06 | $56.65M 10-Q · filed 2025-11-06 | $88.59M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $19.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $47.32M 10-Q · filed 2025-08-07 | $79.26M derived: sum of 3 quarters · filed 2026-02-26 | $99.89M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $27.71M 10-Q · filed 2025-05-08 | $59.65M derived: sum of 2 quarters · filed 2026-02-26 | $80.29M derived: sum of 3 quarters · filed 2026-02-26 | $93.29M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $31.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $52.57M derived: sum of 2 quarters · filed 2026-02-26 | $65.58M derived: sum of 3 quarters · filed 2026-02-26 | $48.16M 10-K · filed 2026-02-26 |
| 2023-09-30 | $20.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $33.64M derived: sum of 2 quarters · filed 2024-11-07 | $16.21M 10-Q · filed 2024-11-07 | $9.02M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $13.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$4.42M 10-Q · filed 2024-08-08 | -$11.62M derived: sum of 3 quarters · filed 2025-02-27 | -$11.16M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$17.43M 10-Q · filed 2024-05-09 | -$24.63M derived: sum of 2 quarters · filed 2025-02-27 | -$24.17M derived: sum of 3 quarters · filed 2025-02-27 | -$29.36M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$7.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$6.74M derived: sum of 2 quarters · filed 2025-02-27 | -$11.93M derived: sum of 3 quarters · filed 2025-02-27 | -$25.00M 10-K · filed 2025-02-27 |
| 2022-09-30 | $457.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$4.73M derived: sum of 2 quarters · filed 2023-11-07 | -$17.80M 10-Q · filed 2023-11-07 | -$42.84M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$5.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$18.26M 10-Q · filed 2023-08-03 | -$43.29M derived: sum of 3 quarters · filed 2024-02-22 | -$35.25M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$13.07M 10-Q · filed 2023-05-04 | -$38.10M derived: sum of 2 quarters · filed 2024-02-22 | -$30.06M derived: sum of 3 quarters · filed 2024-02-22 | |
| 2021-12-31 | -$25.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$16.99M derived: sum of 2 quarters · filed 2024-02-22 | $71.52M 10-K · filed 2024-02-22 | |
| 2021-09-30 | $8.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $96.55M 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $88.50M 10-Q · filed 2022-08-04 | |||
| 2020-12-31 | $26.75M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |